Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.69 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833936 | 0.89 | MAPK14 (0.69) | MAPK14TEKRAF1BRAF | |
| SCHEMBL4829474 | 0.80 | MAPK14 (0.55) | MAPK14TEKRAF1BRAFGBA1 | |
| SCHEMBL4825404 | 0.77 | MAPK14 (0.59) | MAPK14TEKRAF1BRAFMAPK13 | |
| SCHEMBL4829504 | 0.77 | MAPK14 (0.61) | MAPK14RAF1BRAFMAPK13HSPB1 | |
| SCHEMBL5897231 | 0.76 | MAPK14 (0.68) | MAPK14RAF1BRAF | |
| SCHEMBL4831641 | 0.75 | MAPK14 (0.60) | MAPK14RAF1BRAFMAPK13HSPB1 | |
| SCHEMBL4831365 | 0.74 | MAPK14 (0.52) | MAPK14TEKRAF1BRAFMAPK13 | |
| SCHEMBL7845976 | 0.73 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL5897202 | 0.73 | MAPK14 (0.58) | MAPK14RAF1BRAFMAPK13 | |
| SCHEMBL4829619 | 0.72 | MAPK14 (0.51) | MAPK14RAF1BRAFMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | MAPK14 2834/4885TEK 1383/4885RAF1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.